Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029

FinancialNewsMedia.com News Commentary

PALM BEACH, Fla., June 1, 2023 /PRNewswire/ -- Neurofibromatosis is a genetic condition that disrupts the cell growth in your nervous system, causing formation of tumors on nerve tissue. These formed tumors may develop anywhere in the nervous system of the victim, which may include the brain, spinal cord and nerves. Neurofibromatosis is usually diagnosed in childhood or early adulthood. The tumors are noncancerous (benign) in most of the cases, but in some cases these tumors become cancerous (malignant) tumors.  People suffering with neurofibromatosis often experience only mild symptom and effects may range from hearing loss, learning impairment, and heart and blood vessel (cardiovascular) complications to severe disability due to nerve compression by tumors, loss of vision and severe pain. There is no specific treatment for neurofibromatosis, but treatment aims to maximize healthy growth and development and to manage complications as soon as they arise. When neurofibromatosis causes large tumors or tumors that press on a nerve, surgery may help ease symptoms.  A report from Coherent Market Insights projects that the global neurofibromatosis treatment drugs market is expected to exhibit a CAGR of 13.40% through 2027). It said that Increasing focus of major players on research and development of novel therapies for treating neurofibromatosis. Moreover, clinical studies are well supported by regulatory authorities which is expected to drive the growth of the global neurofibromatosis treatment drugs market.   Active Biotechs in the markets today include:  Pasithea Therapeutics Corp. (NASDAQ:KTTA), SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), Day One Biopharmaceuticals (NASDAQ:DAWN), Verastem Oncology, (NASDAQ:VSTM), Kinnate Biopharma Inc. (NASDAQ:KNTE).